Compare VNO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNO | IMVT |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 3145 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | N/A | 2019 |
| Metric | VNO | IMVT |
|---|---|---|
| Price | $38.40 | $31.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $33.00 | $33.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | $7.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.57 | $14.32 |
| 52 Week High | $43.37 | $36.29 |
| Indicator | VNO | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 51.92 |
| Support Level | $38.07 | $22.84 |
| Resistance Level | $40.49 | $36.29 |
| Average True Range (ATR) | 1.03 | 1.97 |
| MACD | 0.40 | -0.32 |
| Stochastic Oscillator | 96.13 | 16.17 |
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.